Harrow Launches Next-Generation Compounded Atropine Formulations

Harrow announced the launch of its patent-pending, next-generation compounded atropine formulations.

The formulations are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx.

According to Harrow, the ImprimisRx next-generation atropine formulations:

• Undergo validated analytical tests to ensure consistency, potency, and stability
• Do not contain either preservatives or boric acid
• Have a physiologic pH of 5.5
• May be stored at room temperature for up to 180 days

“Our mission has always been to help our eye care professionals address their patients’ unmet needs and to make ophthalmic medications both accessible and affordable. The availability of these innovative compounded atropine formulations is in keeping with our mission," Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said in a company news release. "We believe ophthalmologists, optometrists, and the millions of Americans who may benefit from topical atropine therapy will appreciate the tremendous value these patent-pending formulations offer.”

Eye care professionals can order these new compounded atropine formulations for as low as $39 per 5mL bottle–either online at atropine.com or by calling or texting 615‑437‑4690 to speak to ImprimisRx Customer Service.

Compounded medications are not reviewed by the FDA for safety or efficacy. ImprimisRx does not compound copies of commercially available products.